Genmab (CPSE:GMAB) Nears Three Phase III Readouts, Is It Still Undervalued?

Genmab (CPSE:GMAB) is back in focus after management outlined expectations for three pivotal Phase III trial readouts in the coming quarter, tied to cancer therapies it views as potential first in class treatments.

Recent trading reflects that excitement. Genmab’s share price has climbed 32.5% over the past 90 days and delivered a 23.7% total shareholder return over one year. This suggests momentum has picked up as investors weigh the Phase III catalysts against a weaker three and five year total return record.

Scan how Genmab’s late stage pipeline story compares with other potential breakout biotechs by reviewing our hand picked list of 618 high quality undiscovered gems today.

Bulls point to Genmab’s Phase III catalysts and recent 32.5% three month surge, while bears focus on the weaker three and five year record. Which story does the current valuation actually support next?

Most Popular Narrative: 1% Undervalued

Genmab’s most followed narrative pegs fair value at DKK2,303, only slightly above the last close of DKK2,277. This frames the recent rally as roughly in line with that fair value anchor while keeping the Phase III pipeline as the main swing factor.

Strong late-stage pipeline progress, including positive Phase III results for epcoritamab (EPKINLY) and expansion of Rina-S programs, positions Genmab to benefit from the growing global burden of cancer and rising demand for biologic therapies, supporting future revenue and earnings growth.

Strong recurring royalty streams from established partnered products, such as DARZALEX, and a rising contribution from wholly owned product sales underpin predictable cash flows, providing financial flexibility for pipeline investment and margin expansion.

See why 66 investors see Genmab as 1% undervalued.

Result: Fair Value of DKK2,303 (UNDERVALUED)

Still, the Genmab narrative can flip quickly if DARZALEX royalties fade faster than expected or if key late stage trials fail to deliver clearly positive outcomes.

Find out about the key risks to this Genmab narrative.

Next Steps

If this Genmab story feels finely balanced between promise and risk, act while the Phase III narrative is still taking shape. Review the 2 key rewards and 3 important warning signs.

Looking for more ideas beyond Genmab?

If Genmab has your attention, do not stop there. Use the Simply Wall Street Screener to line up your next potential opportunity before others spot it.

• Target rising income by scanning a focused group of 159 dividend fortresses that combine meaningful yield with balance sheet strength.
• Prioritise resilience by reviewing a curated 226 resilient stocks with low risk scores that aim to keep portfolio swings in check.
• Hunt for value by running through a 184 high quality undervalued stocks that blend quality fundamentals with potentially attractive pricing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com